All Type of News
Daewoong introduces Tillots's Asacol in Korea
Daewoong Pharm said it has launched Asacol (mesalazine) in the domestic market, which is the leading drug worldwide for the treatment of Inflammatory Bowel Disease (IBD). It signed a licensing agreement for the exclus...
KFDA approved Yuyu new anti-osteoporosis drug, Maxmavil
Yuyu announced to get the KFDA approval for Maxmavil, a new combined anti-osteoporosis drug formulated with Alrendronate and Calcitriol on Nov. 16 and therefore to launched its sales around coming March next year.
...
NHI reimbursement price to increase 2% next year
The NHI reimbursement price seems to be 2% up from this year by the Health Insurance Policy Council (HIPC) as a result of the negotiation failure between the National Health Insurance Corporation (NHIC) and th...
KFDA budget at less than 0.1% out of all government.
The KFDA's next year budget has been fixed at less than 0.1% out of the total government plan, giving serious concerns about which the food and drug safety control works would be apparently getting harder and of heavy...
Civil group demanding withdrawal of trademark Bacchus-S
A pharmacist group (http://cafe.daum.net/pharmmaker) has called on Dong-A Pharm to withdraw the possible use of a controversial trademark 'Bacchus-S', a quasi-drug, as it might lead an end-user to believe that Bacchus...
90 percent of Koreans with COPD under non-medical diagnosis
According to the survey of 200 COPD patients or those exposed to high risk of the disease in 10 regions across the nation conducted by the Korean Society of Respiratory and the Korea Health and Social Affairs Research...
Korean national named first Asian clinical research coordinator
Novartis Korea announced the appointment of Kang Ja-hoon, currently assistant manager of the company's Clinical and Medical Division, to the position of Asian clinical research coordinator in International Clinical Re...
Sharp bipolar phenomenon in pharmaceutical economy.
Although overall business in the pharmaceutical industries showed an ongoing rise, there appeared with a severe disparity among the companies.
The business achievement up to the 3rd quarter this year after 2003 rec...
Government will allow Korean Nationals to use foreign hospitals in FEZ
The government decided to allow local residents to receive medical services at foreign-invested hospitals in the free economic zones to be set up in Inchon, Pusan and Kwangju during a Cabinet meeting on November 16.
...
Pfizer Korea's counter attacks for Norvasc defence.
Pfizer Korea began to counter attack against the Norvasc rival products by quoting their survey data describing a superior product position to other rivals in terms of its efficacy and safety proven for a long time.
...
